The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LYEL | -13.26% | N/A | N/A | -95% |
| S&P | +19.89% | +109.18% | +15.89% | +62% |
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.01M | -38.5% |
| Gross Profit | -$3.13M | 36.0% |
| Gross Margin | -39087.50% | -1487.5% |
| Market Cap | $130.90M | -64.6% |
| Market Cap / Employee | $0.44M | 0.0% |
| Employees | 300 | 33.9% |
| Net Income | -$42.68M | 6.8% |
| EBITDA | -$41.50M | 14.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $98.80M | -25.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $46.60M | -12.6% |
| Short Term Debt | $0.00M | -100.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -63.76% | -35.5% |
| Return On Invested Capital | -36.92% | -9.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$34.63M | 9.9% |
| Operating Free Cash Flow | -$34.46M | 9.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.67 | 0.49 | 0.47 | 0.39 | -36.72% |
| Price to Sales | 5614.39 | 2796.47 | 2442.50 | 2179.50 | -68.22% |
| Price to Tangible Book Value | 13.34 | 6.19 | 8.29 | 0.39 | -96.84% |
| Enterprise Value to EBITDA | 0.61 | 2.42 | 1.58 | 2.40 | 91.42% |
| Return on Equity | -33.2% | -66.1% | -71.2% | -76.6% | 137.37% |
| Total Debt | $58.58M | $58.97M | $57.09M | $46.60M | -22.62% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
